Professor of Translational Haematology, University of Leipzig, Germany
Professor Metzeler is a hemato-oncologist and physician who has pursued molecular cancer genetics throughout his career.
Following early work in the establishment of an NGS testing program for hematological malignancies he has gone on to research translational biomarker studies in myeloid neoplasms including MRD, the genetics and clinical relevance of clonal hematopoiesis, and quality of life in AML survivors.
Prof. Dr. med. Klaus H. Metzeler, MD, Professor of Translational Haematology, University of Leipzig, Germany
In this AMP 2023 session, Professor Metzeler describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in acute myeloid leukemia (AML), including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.
His results highlight the breadth of clinically relevant variants, including FLT3-ITD mutations, being confidently detected by NGS and the potential application of the SureSeq Myeloid MRD Panel as a tool for further investigation of MRD in AML samples.
This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.
SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.
Call +44 (0)1865 856800 Email contact@ogt.com
Send us a message and we will get back to you
Visit International site
Visit USA site